Navigation Links
Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Date:9/7/2007

BALTIMORE, Sept. 7 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Betsy Van Parijs, M.D., Ph.D. to Senior Vice President, Clinical Development and Medical Affairs. In this role, Dr. Van Parijs will be responsible for leading Alba's clinical development strategy and program execution through product approval and commercialization. Dr. Van Parijs will also serve as a member of Alba's executive management leadership team.

"We are very pleased to announce that Dr. Van Parijs is joining Alba in this critical leadership role. Betsy is an accomplished executive with extensive experience in clinical development including the development, execution and validation of a patient-reported outcomes (PRO) instrument as a new primary efficacy endpoint for clinical trials," said Blake Paterson, M.D., Alba's Chief Executive Officer. "Her leadership in our efforts to validate the celiac disease activity rating score in our upcoming Phase II clinical trials will be essential for the success of AT-1001 as the first drug for celiac disease," added Dr. Paterson.

"Alba has a singular approach to the treatment of seemingly diverse clinical syndromes. Its discovery engine and clinical path offer the promise of redefining the pathogenesis and treatment of certain autoimmune diseases. I am delighted to join such a dedicated and innovative organization," said Dr. Van Parijs.

Prior to joining Alba, Dr. Van Parijs held senior level positions in clinical development (phases II-IV) and medical affairs at two multinational pharmaceutical companies. From 2003 to 2007, Dr. Van Parijs served as Senior Director, Clinical Development and Medical Affairs in the Infectious Diseases Center (Anti-Infectives) at GlaxoSmithKline (GSK) where she was responsible for directing the clinical sections of regulatory submissions, defining and implementing later phase clinical strategy for Anti-Infectives in the pipeline, and for medical affairs, including promotional review activities of the late phase group focusing on marketed products. Dr. Van Parijs also led the development, execution and validation of a new primary efficacy endpoint for clinical trials in acute exacerbations of COPD (AECOPD). From 2001-2002, Dr. Van Parijs served as Director, Global Medical Affairs (Vaccines) at Wyeth. She also led the clinical development through to submission and market support of some vaccines for GSK earlier, enhancing her experience in the application of clinical immunology to the clinical development, submission and commercialization process.

Dr. Van Parijs holds a Ph.D. in Neuroscience and earned her M.D. from Christian Medical College, Vellore, University of Madras in Tamil Nadu, India. She has published numerous research and clinical development articles and has received various honors including GSK's R&D Silver Award for Leadership in Developing a New Patient-Reported Outcomes Instrument for AECOPD.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to the development and commercialization of disease-modifying therapeutics to treat autoimmune and inflammatory diseases, drug delivery agents and mucosal vaccine adjuvants by exploiting its technology to regulate the assembly and disassembly of tight junctions in cell barriers throughout the body. Alba's lead compound, AT-1001, is targeted toward the treatment of Celiac Disease, Inflammatory Bowel Disease and Type 1 Diabetes.

Contact: Dr. Bernard McDonald

Phone: 410-319-0780

E-mail: info@albatherapeutics.com

Website: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sharon Ethanol appoints operations director
3. Kyron appoints former AMA chairman to board
4. Brady appoints GE efficiency expert as CTO
5. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
6. Johnson Controls appoints Roell to head EOC
7. SecurePipe appoints two senior execs
8. Milwaukees PointOne appoints new president and CEO
9. Third Wave appoints new chairman
10. Midwest Venture Summit disappoints; Cato grades Midwest governors
11. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):